Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Vorinostat"" wg kryterium: Temat


Tytuł :
Pre- and Post-Transcriptional Regulation of cFLIP for Effective Cancer Therapy Using pH-Ultrasensitive Nanoparticles.
Autorzy :
Phung CD; College of Pharmacy, Yeungnam University, Gyeongsan 38541, Republic of Korea.
Tran TH; Faculty of Pharmacy, PHENIKAA University, Yen Nghia, Ha Dong, Hanoi 12116, Vietnam.; PHENIKAA Research and Technology Institute (PRATI), A&A Green Phoenix Group JSC, No. 167 Hoang Ngan, Trung Hoa, Cau Giay, Hanoi 11313, Vietnam.
Choi JY; College of Pharmacy, Yeungnam University, Gyeongsan 38541, Republic of Korea.
Jeong JH; College of Pharmacy, Yeungnam University, Gyeongsan 38541, Republic of Korea.
Ku SK; College of Korean Medicine, Daegu Haany University, Gyeongsan 38610, Republic of Korea.
Yong CS; College of Pharmacy, Yeungnam University, Gyeongsan 38541, Republic of Korea.
Kim JO; College of Pharmacy, Yeungnam University, Gyeongsan 38541, Republic of Korea.
Pokaż więcej
Źródło :
ACS applied materials & interfaces [ACS Appl Mater Interfaces] 2021 Feb 10; Vol. 13 (5), pp. 5999-6010. Date of Electronic Publication: 2021 Jan 28.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*pharmacology
CASP8 and FADD-Like Apoptosis Regulating Protein/*antagonists & inhibitors
CASP8 and FADD-Like Apoptosis Regulating Protein/*genetics
Nanoparticles/*chemistry
RNA, Small Interfering/*pharmacology
Vorinostat/*pharmacology
Animals ; Antineoplastic Agents/chemistry ; CASP8 and FADD-Like Apoptosis Regulating Protein/metabolism ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Drug Screening Assays, Antitumor ; Female ; Humans ; Hydrogen-Ion Concentration ; Mice ; Mice, Inbred BALB C ; Neoplasms, Experimental/drug therapy ; Neoplasms, Experimental/metabolism ; Neoplasms, Experimental/pathology ; Particle Size ; Polyethylene Glycols/chemistry ; RNA, Small Interfering/chemistry ; Surface Properties ; Vorinostat/chemistry
Czasopismo naukowe
Tytuł :
A G-Quadruplex-Binding Small Molecule and the HDAC Inhibitor SAHA (Vorinostat) Act Synergistically in Gemcitabine-Sensitive and Resistant Pancreatic Cancer Cells.
Autorzy :
Ahmed AA; School of Pharmacy, University College London, London WC1N 1AX, UK.
Neidle S; School of Pharmacy, University College London, London WC1N 1AX, UK.
Pokaż więcej
Źródło :
Molecules (Basel, Switzerland) [Molecules] 2020 Nov 19; Vol. 25 (22). Date of Electronic Publication: 2020 Nov 19.
Typ publikacji :
Journal Article
MeSH Terms :
G-Quadruplexes*
Deoxycytidine/*analogs & derivatives
Drug Resistance, Neoplasm/*drug effects
Histone Deacetylase Inhibitors/*therapeutic use
Pancreatic Neoplasms/*drug therapy
Small Molecule Libraries/*pharmacology
Vorinostat/*therapeutic use
Cell Line, Tumor ; DNA Damage ; Deoxycytidine/pharmacology ; Deoxycytidine/therapeutic use ; Drug Synergism ; Epigenesis, Genetic/drug effects ; Gene Expression Regulation, Neoplastic/drug effects ; Histone Deacetylase Inhibitors/pharmacology ; Humans ; Pancreatic Neoplasms/pathology ; Vorinostat/chemistry ; Vorinostat/pharmacology
Czasopismo naukowe
Tytuł :
Vorinostat is genotoxic and epigenotoxic in the mouse bone marrow cells at the human equivalent doses.
Autorzy :
Attia SM; College of Pharmacy, Pharmacology and Toxicology Department, King Saud University, Riyadh, Saudi Arabia. Electronic address: .
Al-Khalifa MK; College of Pharmacy, Pharmacology and Toxicology Department, King Saud University, Riyadh, Saudi Arabia.
Al-Hamamah MA; College of Pharmacy, Pharmacology and Toxicology Department, King Saud University, Riyadh, Saudi Arabia.
Alotaibi MR; College of Pharmacy, Pharmacology and Toxicology Department, King Saud University, Riyadh, Saudi Arabia.
Attia MSM; College of Pharmacy, Pharmacology and Toxicology Department, King Saud University, Riyadh, Saudi Arabia.
Ahmad SF; College of Pharmacy, Pharmacology and Toxicology Department, King Saud University, Riyadh, Saudi Arabia.
Ansari MA; College of Pharmacy, Pharmacology and Toxicology Department, King Saud University, Riyadh, Saudi Arabia.
Nadeem A; College of Pharmacy, Pharmacology and Toxicology Department, King Saud University, Riyadh, Saudi Arabia.
Bakheet SA; College of Pharmacy, Pharmacology and Toxicology Department, King Saud University, Riyadh, Saudi Arabia.
Pokaż więcej
Źródło :
Toxicology [Toxicology] 2020 Aug; Vol. 441, pp. 152507. Date of Electronic Publication: 2020 Jun 05.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*toxicity
Bone Marrow Cells/*drug effects
Vorinostat/*toxicity
Animals ; Antineoplastic Agents/administration & dosage ; Apoptosis/drug effects ; Chromosome Aberrations/chemically induced ; Comet Assay ; DNA Methylation/drug effects ; DNA Repair/drug effects ; Dose-Response Relationship, Drug ; Down-Regulation ; Male ; Mice ; Oxidative Stress/drug effects ; Vorinostat/administration & dosage
Czasopismo naukowe
Tytuł :
Novel copper-based and pH-sensitive nanomedicine for enhanced chemodynamic therapy.
Autorzy :
Wang L; State Key Laboratory of Pharmaceutical Biotechnology, Medical School of Nanjing University & School of Life Sciences, Nanjing University, Nanjing 210093, P. R. China. .
Zhang Z; State Key Laboratory of Pharmaceutical Biotechnology, Medical School of Nanjing University & School of Life Sciences, Nanjing University, Nanjing 210093, P. R. China. .
Ding Y; State Key Laboratory of Pharmaceutical Biotechnology, Medical School of Nanjing University & School of Life Sciences, Nanjing University, Nanjing 210093, P. R. China. .
Wu J; State Key Laboratory of Pharmaceutical Biotechnology, Medical School of Nanjing University & School of Life Sciences, Nanjing University, Nanjing 210093, P. R. China. and Institute of Drug R&D, Nanjing University, Nanjing 210093, P. R. China and Jiangsu Provincial Key Laboratory for Nano Technology, Nanjing University, Nanjing, 210093, P. R. China.
Hu Y; State Key Laboratory of Pharmaceutical Biotechnology, Medical School of Nanjing University & School of Life Sciences, Nanjing University, Nanjing 210093, P. R. China. and Institute of Drug R&D, Nanjing University, Nanjing 210093, P. R. China and Jiangsu Provincial Key Laboratory for Nano Technology, Nanjing University, Nanjing, 210093, P. R. China.
Yuan A; State Key Laboratory of Pharmaceutical Biotechnology, Medical School of Nanjing University & School of Life Sciences, Nanjing University, Nanjing 210093, P. R. China. and Institute of Drug R&D, Nanjing University, Nanjing 210093, P. R. China and Jiangsu Provincial Key Laboratory for Nano Technology, Nanjing University, Nanjing, 210093, P. R. China.
Pokaż więcej
Źródło :
Chemical communications (Cambridge, England) [Chem Commun (Camb)] 2020 Jul 14; Vol. 56 (56), pp. 7753-7756.
Typ publikacji :
Journal Article
MeSH Terms :
Hydrogen-Ion Concentration*
Copper/*chemistry
Metal Nanoparticles/*chemistry
Molecular Targeted Therapy/*methods
Vorinostat/*pharmacology
Animals ; Cell Line, Tumor ; Coordination Complexes/chemistry ; Histone Deacetylase Inhibitors/chemistry ; Histone Deacetylase Inhibitors/pharmacokinetics ; Histone Deacetylase Inhibitors/pharmacology ; Humans ; Mice ; Vorinostat/chemistry ; Vorinostat/pharmacokinetics
Czasopismo naukowe
Tytuł :
Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat.
Autorzy :
Maxwell JW; Merck & Co., Inc., West Point, Pennsylvania, USA .
Falcinelli SD; UNC HIV Cure Center, University of North Carolina, Chapel Hill, North Carolina, USA.; Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina, USA.
Nefedov A; Merck & Co., Inc., West Point, Pennsylvania, USA.
Dorfmeier C; Merck & Co., Inc., West Point, Pennsylvania, USA.
Wu G; Merck & Co., Inc., West Point, Pennsylvania, USA.
Dewey M; UNC HIV Cure Center, University of North Carolina, Chapel Hill, North Carolina, USA.
Webber AL; Merck & Co., Inc., West Point, Pennsylvania, USA.
Archin NM; UNC HIV Cure Center, University of North Carolina, Chapel Hill, North Carolina, USA .; Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
Margolis DM; UNC HIV Cure Center, University of North Carolina, Chapel Hill, North Carolina, USA.; Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina, USA.; Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
Hazuda DJ; Merck & Co., Inc., West Point, Pennsylvania, USA.
Barnard RJO; Merck & Co., Inc., West Point, Pennsylvania, USA.
Howell BJ; Merck & Co., Inc., West Point, Pennsylvania, USA.
Pokaż więcej
Źródło :
Journal of virology [J Virol] 2020 Jun 16; Vol. 94 (13). Date of Electronic Publication: 2020 Jun 16 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
CD4-Positive T-Lymphocytes/*metabolism
HIV Infections/*drug therapy
Vorinostat/*pharmacology
Acetylation ; CD4-Positive T-Lymphocytes/drug effects ; HIV-1/metabolism ; HIV-1/pathogenicity ; Histone Deacetylase Inhibitors/pharmacology ; Humans ; Jurkat Cells ; Leukocytes, Mononuclear/drug effects ; Primary Cell Culture ; Virus Activation/drug effects ; Virus Latency/drug effects ; Vorinostat/metabolism
Czasopismo naukowe
Tytuł :
Vorinostat upregulates MICA via the PI3K/Akt pathway to enhance the ability of natural killer cells to kill tumor cells.
Autorzy :
Xia C; The College of Pharmacy in Guangzhou Medical University, Guangzhou, 510150, China; Foshan Maternal and Child Health Research Institute, South Medical University Affiliated Maternal & Child Health Hospital of Foshan, Foshan, 528000, China. Electronic address: .
He Z; The College of Pharmacy in Guangzhou Medical University, Guangzhou, 510150, China.
Cai Y; Department of Dermatology and Rheumatology, Foshan Women and Children's Hospital Affiliated to Southern Medical University, Foshan, 528000, China.
Liang S; The College of Pharmacy in Guangzhou Medical University, Guangzhou, 510150, China; Foshan Maternal and Child Health Research Institute, South Medical University Affiliated Maternal & Child Health Hospital of Foshan, Foshan, 528000, China.
Pokaż więcej
Źródło :
European journal of pharmacology [Eur J Pharmacol] 2020 May 15; Vol. 875, pp. 173057. Date of Electronic Publication: 2020 Mar 02.
Typ publikacji :
Journal Article
MeSH Terms :
Histocompatibility Antigens Class I/*metabolism
Histone Deacetylase Inhibitors/*pharmacology
Killer Cells, Natural/*immunology
Uterine Cervical Neoplasms/*drug therapy
Vorinostat/*pharmacology
Animals ; Apoptosis/drug effects ; Cell Cycle Checkpoints/drug effects ; Cell Line, Tumor ; Cell Movement/drug effects ; Cell Proliferation/drug effects ; Female ; Gene Expression Regulation, Neoplastic/drug effects ; Histone Deacetylase Inhibitors/therapeutic use ; Humans ; Killer Cells, Natural/drug effects ; Mice ; Neoplasm Invasiveness/prevention & control ; Phosphatidylinositol 3-Kinases/metabolism ; Proto-Oncogene Proteins c-akt/metabolism ; Up-Regulation/drug effects ; Uterine Cervical Neoplasms/pathology ; Vorinostat/therapeutic use ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
A distal regulatory region of a class I human histone deacetylase.
Autorzy :
Werbeck ND; Institute of Structural and Molecular Biology, Division of Biosciences, University College London, London, WC1E 6BT, UK.; Nuvisan ICB GmbH, Innovation Campus Berlin, Müllerstraße 178, 13353, Berlin, Germany.
Shukla VK; Institute of Structural and Molecular Biology, Division of Biosciences, University College London, London, WC1E 6BT, UK.
Kunze MBA; Institute of Structural and Molecular Biology, Division of Biosciences, University College London, London, WC1E 6BT, UK.
Yalinca H; Institute of Structural and Molecular Biology, Division of Biosciences, University College London, London, WC1E 6BT, UK.
Pritchard RB; Institute of Structural and Molecular Biology, Division of Biosciences, University College London, London, WC1E 6BT, UK.
Siemons L; Institute of Structural and Molecular Biology, Division of Biosciences, University College London, London, WC1E 6BT, UK.
Mondal S; Institute of Structural and Molecular Biology, Division of Biosciences, University College London, London, WC1E 6BT, UK.
Greenwood SOR; Institute of Structural and Molecular Biology, Division of Biosciences, University College London, London, WC1E 6BT, UK.; Department of Chemistry, University College London, London, WC1E 6BT, UK.
Kirkpatrick J; Institute of Structural and Molecular Biology, Division of Biosciences, University College London, London, WC1E 6BT, UK.
Marson CM; Department of Chemistry, University College London, London, WC1E 6BT, UK.
Hansen DF; Institute of Structural and Molecular Biology, Division of Biosciences, University College London, London, WC1E 6BT, UK. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2020 Jul 31; Vol. 11 (1), pp. 3841. Date of Electronic Publication: 2020 Jul 31.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Histone Deacetylase Inhibitors/*chemistry
Histone Deacetylases/*chemistry
Hydroxamic Acids/*chemistry
Indoles/*chemistry
Repressor Proteins/*chemistry
Vorinostat/*chemistry
Allosteric Regulation ; Allosteric Site ; Catalytic Domain ; Cloning, Molecular ; Crystallography, X-Ray ; Enzyme Activation ; Escherichia coli/genetics ; Escherichia coli/metabolism ; Gene Expression ; Genetic Vectors/chemistry ; Genetic Vectors/metabolism ; Histone Deacetylase Inhibitors/metabolism ; Histone Deacetylases/genetics ; Histone Deacetylases/metabolism ; Humans ; Hydroxamic Acids/metabolism ; Indoles/metabolism ; Molecular Dynamics Simulation ; Mutation ; Protein Binding ; Protein Conformation, alpha-Helical ; Protein Conformation, beta-Strand ; Protein Interaction Domains and Motifs ; Recombinant Proteins/chemistry ; Recombinant Proteins/genetics ; Recombinant Proteins/metabolism ; Repressor Proteins/antagonists & inhibitors ; Repressor Proteins/genetics ; Repressor Proteins/metabolism ; Substrate Specificity ; Thermodynamics ; Vorinostat/metabolism
Czasopismo naukowe
Tytuł :
Novel SAHA‑bendamustine hybrid NL‑101 in combination with daunorubicin synergistically suppresses acute myeloid leukemia.
Autorzy :
Jin J; Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang 310003, P.R. China.
Li X; Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang 310003, P.R. China.
Guo W; Department of Hematology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325027, P.R. China.
Li F; Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang 310003, P.R. China.
Huang J; Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang 310003, P.R. China.
Huang X; Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang 310003, P.R. China.
Pan J; Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang 310003, P.R. China.
Huang S; Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang 310003, P.R. China.
Ye W; Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang 310003, P.R. China.
Ling Q; Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang 310003, P.R. China.
Jin J; Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang 310003, P.R. China.
Pokaż więcej
Źródło :
Oncology reports [Oncol Rep] 2020 Jul; Vol. 44 (1), pp. 273-282. Date of Electronic Publication: 2020 Apr 22.
Typ publikacji :
Journal Article
MeSH Terms :
Bendamustine Hydrochloride/*administration & dosage
Daunorubicin/*administration & dosage
Leukemia, Myeloid, Acute/*drug therapy
Vorinostat/*administration & dosage
Animals ; Bendamustine Hydrochloride/pharmacology ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; DNA Damage ; Daunorubicin/pharmacology ; Drug Synergism ; Female ; HL-60 Cells ; Humans ; Leukemia, Myeloid, Acute/genetics ; Mice ; Vorinostat/pharmacology ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies.
Autorzy :
Wang Y; Departments of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, Hebei, People's Republic of China.
Janku F; Departments of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Piha-Paul S; Departments of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hess K; Departments of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Broaddus R; Departments of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Liu L; Departments of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shi N; Departments of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Overman M; Departments of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kopetz S; Departments of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Subbiah V; Departments of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Naing A; Departments of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hong D; Departments of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Tsimberidou AM; Departments of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Karp D; Departments of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yao J; Departments of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Fu S; Departments of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Feb 20; Vol. 10 (1), pp. 3080. Date of Electronic Publication: 2020 Feb 20.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Angiogenesis Inhibitors/*therapeutic use
Boron Compounds/*therapeutic use
Glycine/*analogs & derivatives
Mutation/*genetics
Neoplasms/*drug therapy
Neoplasms/*genetics
Pyrimidines/*therapeutic use
Sulfonamides/*therapeutic use
Tumor Suppressor Protein p53/*genetics
Vorinostat/*therapeutic use
Adult ; Aged ; Angiogenesis Inhibitors/adverse effects ; Angiogenesis Inhibitors/pharmacology ; Boron Compounds/adverse effects ; Boron Compounds/pharmacology ; Glycine/adverse effects ; Glycine/pharmacology ; Glycine/therapeutic use ; Humans ; Kaplan-Meier Estimate ; Middle Aged ; Progression-Free Survival ; Pyrimidines/adverse effects ; Pyrimidines/pharmacology ; Sulfonamides/adverse effects ; Sulfonamides/pharmacology ; Treatment Outcome ; Vorinostat/adverse effects ; Vorinostat/pharmacology ; Young Adult
Czasopismo naukowe
Tytuł :
A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects.
Autorzy :
Huang M; Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Xie X; Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Gong P; Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Wei Y; Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Du H; Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Xu Y; Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Xu Q; Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Jing Y; Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China; Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, 110016, China. Electronic address: .
Zhao L; Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China. Electronic address: .
Pokaż więcej
Źródło :
European journal of medicinal chemistry [Eur J Med Chem] 2020 Feb 15; Vol. 188, pp. 111991. Date of Electronic Publication: 2019 Dec 20.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*pharmacology
Glycyrrhetinic Acid/*analogs & derivatives
Histone Deacetylase 6/*metabolism
Vorinostat/*analogs & derivatives
Vorinostat/*pharmacology
Acetylation ; Animals ; Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/pharmacokinetics ; Apoptosis/drug effects ; Cell Line, Tumor ; Glycyrrhetinic Acid/pharmacokinetics ; Glycyrrhetinic Acid/pharmacology ; Histone Deacetylases/metabolism ; Histones/metabolism ; Humans ; Male ; Rats, Sprague-Dawley ; Tubulin/chemistry ; Tubulin/metabolism ; Vorinostat/pharmacokinetics
Czasopismo naukowe
Tytuł :
Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer.
Autorzy :
Takeuchi S; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.; Nano Life Science Institute, Kanazawa University, Kanazawa, Japan.
Hase T; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Shimizu S; Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.
Ando M; Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.
Hata A; Division of Integrated Oncology, Institute of Biomedical Research and Innovation, Kobe, Japan.; Department of Medical Oncology, Kobe Minimally Invasive Cancer Center, Kobe, Japan.
Murakami H; Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Kawakami T; Innovative Clinical Research Center (iCREK), Kanazawa University Hospital, Kanazawa, Japan.
Nagase K; Innovative Clinical Research Center (iCREK), Kanazawa University Hospital, Kanazawa, Japan.
Yoshimura K; Innovative Clinical Research Center (iCREK), Kanazawa University Hospital, Kanazawa, Japan.; Department of Data Science, Center for Integrated Medical Research, Hiroshima University Hospital, Hiroshima, Japan.
Fujiwara T; Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.; Clinical Research Center, Chiba University Hospital, Chiba, Japan.
Tanimoto A; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Nishiyama A; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Arai S; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Fukuda K; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.; Nano Life Science Institute, Kanazawa University, Kanazawa, Japan.
Katakami N; Division of Integrated Oncology, Institute of Biomedical Research and Innovation, Kobe, Japan.; Department of Medical Oncology, Takarazuka City Hospital, Takarazuka, Japan.
Takahashi T; Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Hasegawa Y; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.; National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Ko TK; Cancer and Stem Cell Biology Signature Research Program, Duke-NUS Medical School, Singapore.
Ong ST; Cancer and Stem Cell Biology Signature Research Program, Duke-NUS Medical School, Singapore.; Department of Haematology, Singapore General Hospital, Singapore.; Department of Medical Oncology, National Cancer Centre Singapore, Singapore.; Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
Yano S; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.; Nano Life Science Institute, Kanazawa University, Kanazawa, Japan.
Pokaż więcej
Źródło :
Cancer science [Cancer Sci] 2020 Feb; Vol. 111 (2), pp. 561-570. Date of Electronic Publication: 2020 Jan 06.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Multicenter Study
MeSH Terms :
Bcl-2-Like Protein 11/*genetics
Carcinoma, Non-Small-Cell Lung/*drug therapy
Gefitinib/*administration & dosage
Lung Neoplasms/*drug therapy
Vorinostat/*administration & dosage
Aged ; Aged, 80 and over ; Carcinoma, Non-Small-Cell Lung/genetics ; Drug Administration Schedule ; ErbB Receptors/genetics ; Female ; Gefitinib/pharmacokinetics ; Humans ; Lung Neoplasms/genetics ; Male ; Middle Aged ; Mutation ; Sequence Deletion ; Survival Analysis ; Treatment Outcome ; Vorinostat/pharmacokinetics
Czasopismo naukowe
Tytuł :
Vorinostat, a possible alternative to metronidazole for the treatment of amebiasis caused by Entamoeba histolytica .
Autorzy :
Montaño S; Laboratorio de Bioinformática, Facultad de Ciencias Químico-Biológicas, Universidad Autónoma de Sinaloa (FCQB-UAS), Blvd. de las Américas y Josefa Ortiz de Domínguez s/n. Ciudad Universitaria, Culiacán Sinaloa, México.
Constantino-Jonapa LA; Centro de Investigación y de Estudios Avanzados del IPN (CINVESTAV -IPN), Mexico City, México.
Sixto-López Y; Laboratorio de Modelado Molecular, Bioinformática y Diseño de Fármacos, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, CDMX, México.
Hernández-Ramírez VI; Centro de Investigación y de Estudios Avanzados del IPN (CINVESTAV -IPN), Mexico City, México.
Hernández-Ceruelos A; Área Académica de Medicina, Instituto de Ciencias de la Salud, Universidad Autónoma del Estado de Hidalgo, Circuito Ex Hacienda La Concepción S/N Carretera Pachuca-Actopan, San Agustín Tlaxiaca, Hidalgo, México.
Romero-Quezada LC; Área Académica de Medicina, Instituto de Ciencias de la Salud, Universidad Autónoma del Estado de Hidalgo, Circuito Ex Hacienda La Concepción S/N Carretera Pachuca-Actopan, San Agustín Tlaxiaca, Hidalgo, México.
Ruvalcaba-Ledezma JC; Área Académica de Medicina, Instituto de Ciencias de la Salud, Universidad Autónoma del Estado de Hidalgo, Circuito Ex Hacienda La Concepción S/N Carretera Pachuca-Actopan, San Agustín Tlaxiaca, Hidalgo, México.
Talamás-Rohana P; Centro de Investigación y de Estudios Avanzados del IPN (CINVESTAV -IPN), Mexico City, México.
López-Contreras L; Área Académica de Medicina, Instituto de Ciencias de la Salud, Universidad Autónoma del Estado de Hidalgo, Circuito Ex Hacienda La Concepción S/N Carretera Pachuca-Actopan, San Agustín Tlaxiaca, Hidalgo, México.
Pokaż więcej
Źródło :
Journal of biomolecular structure & dynamics [J Biomol Struct Dyn] 2020 Feb; Vol. 38 (2), pp. 597-603. Date of Electronic Publication: 2019 Apr 26.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Amebiasis/*drug therapy
Amebiasis/*parasitology
Entamoeba histolytica/*physiology
Metronidazole/*therapeutic use
Vorinostat/*therapeutic use
Entamoeba histolytica/drug effects ; Entamoeba histolytica/enzymology ; Histone Deacetylases/chemistry ; Metronidazole/chemistry ; Metronidazole/pharmacology ; Molecular Docking Simulation ; Molecular Dynamics Simulation ; Phylogeny ; Structural Homology, Protein ; Trophozoites/drug effects ; Trophozoites/physiology ; Vorinostat/chemistry ; Vorinostat/pharmacology
Raport
Tytuł :
Systematic analysis to identify transcriptome-wide dysregulation of Alzheimer's disease in genes and isoforms.
Autorzy :
Fan C; Department of Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 107 Yan Jiang West Road, Guangzhou, 500001, People's Republic of China.; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangzhou, 510220, People's Republic of China.
Chen K; School of Data and Computer Science, Sun Yat-Sen University, Guangzhou, 510000, People's Republic of China.
Zhou J; Department of Anesthesiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510289, People's Republic of China.
Wong PP; Department of Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 107 Yan Jiang West Road, Guangzhou, 500001, People's Republic of China.; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangzhou, 510220, People's Republic of China.
He D; Department of Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 107 Yan Jiang West Road, Guangzhou, 500001, People's Republic of China.
Huang Y; School of Mathematics, Sun Yat-Sen University, Guangzhou, 510275, People's Republic of China.
Wang X; School of Life Sciences, Sun Yat-Sen University, Guangzhou, 510006, People's Republic of China.
Ling T; School of Life Sciences, Sun Yat-Sen University, Guangzhou, 510006, People's Republic of China.
Yang Y; School of Data and Computer Science, Sun Yat-Sen University, Guangzhou, 510000, People's Republic of China.
Zhao H; Department of Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 107 Yan Jiang West Road, Guangzhou, 500001, People's Republic of China. .; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangzhou, 510220, People's Republic of China. .
Pokaż więcej
Źródło :
Human genetics [Hum Genet] 2021 Apr; Vol. 140 (4), pp. 609-623. Date of Electronic Publication: 2020 Nov 02.
Typ publikacji :
Journal Article
MeSH Terms :
Gene Expression Regulation*
Gene Regulatory Networks*
Transcriptome*
Alzheimer Disease/*genetics
Protein Isoforms/*genetics
Alternative Splicing ; Alzheimer Disease/drug therapy ; Datasets as Topic ; Female ; Genome-Wide Association Study ; Humans ; Male ; Polymorphism, Single Nucleotide ; Prefrontal Cortex/metabolism ; RNA Splicing ; RNA-Seq ; Tacrolimus/therapeutic use ; Vorinostat/therapeutic use
Czasopismo naukowe
Tytuł :
Chemical screens in a zebrafish model of CHARGE syndrome identifies small molecules that ameliorate disease-like phenotypes in embryo.
Autorzy :
Asad Z; CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), New Delhi, 110025, India; Academy of Scientific and Innovative Research (AcSIR), New Delhi, India.
Sachidanandan C; CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), New Delhi, 110025, India; Academy of Scientific and Innovative Research (AcSIR), New Delhi, India. Electronic address: .
Pokaż więcej
Źródło :
European journal of medical genetics [Eur J Med Genet] 2020 Feb; Vol. 63 (2), pp. 103661. Date of Electronic Publication: 2019 May 01.
Typ publikacji :
Journal Article
MeSH Terms :
CHARGE Syndrome/*drug therapy
CHARGE Syndrome/*physiopathology
DNA Helicases/*genetics
DNA-Binding Proteins/*genetics
Dipeptides/*pharmacology
Procainamide/*pharmacology
Vorinostat/*pharmacology
Zebrafish/*embryology
Zebrafish Proteins/*genetics
Animals ; Animals, Genetically Modified ; CHARGE Syndrome/genetics ; Cartilage/drug effects ; Cartilage/pathology ; DNA (Cytosine-5-)-Methyltransferase 1/antagonists & inhibitors ; DNA Helicases/metabolism ; DNA-Binding Proteins/metabolism ; Dipeptides/therapeutic use ; Disease Models, Animal ; Embryo, Nonmammalian/diagnostic imaging ; Embryo, Nonmammalian/drug effects ; Embryo, Nonmammalian/metabolism ; Embryo, Nonmammalian/physiopathology ; Gene Knockdown Techniques ; Histone Deacetylase Inhibitors/pharmacology ; Histone Deacetylase Inhibitors/therapeutic use ; LIM-Homeodomain Proteins/genetics ; LIM-Homeodomain Proteins/metabolism ; Nerve Fibers, Myelinated/drug effects ; Nerve Fibers, Myelinated/pathology ; Neurons/drug effects ; Neurons/pathology ; Procainamide/therapeutic use ; Receptors, Notch/antagonists & inhibitors ; Sirtuin 1/antagonists & inhibitors ; Transcription Factors/genetics ; Transcription Factors/metabolism ; Vorinostat/therapeutic use ; Zebrafish/genetics ; Zebrafish Proteins/metabolism
Czasopismo naukowe
Tytuł :
Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia.
Autorzy :
van Tilburg CM; KiTZ Clinical Trial Unit, Hopp Children's Cancer Center Heidelberg (KiTZ), German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany.; Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital, Heidelberg, Germany.; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.
Milde T; KiTZ Clinical Trial Unit, Hopp Children's Cancer Center Heidelberg (KiTZ), German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany.; Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital, Heidelberg, Germany.; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.
Witt R; KiTZ Clinical Trial Unit, Hopp Children's Cancer Center Heidelberg (KiTZ), German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany.; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.
Ecker J; KiTZ Clinical Trial Unit, Hopp Children's Cancer Center Heidelberg (KiTZ), German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany.; Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital, Heidelberg, Germany.; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.
Hielscher T; Division of Biostatistics, German Cancer Research Center (DKFZ) and German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany.
Seitz A; Division of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.
Schenk JP; Division of Pediatric Radiology, Heidelberg University Hospital, Heidelberg, Germany.
Buhl JL; KiTZ Clinical Trial Unit, Hopp Children's Cancer Center Heidelberg (KiTZ), German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany.; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
Riehl D; DKTK Immune Monitoring Unit, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Frühwald MC; Swabian Children's Cancer Center, University Children's Hospital Augsburg, Augsburg, Germany.
Pekrun A; Children's Hospital, Bremen, Germany.
Rossig C; Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster, Germany.
Wieland R; Department of Pediatric Oncology and Hematology, Essen University Hospital, Essen, Germany.
Flotho C; Division of Pediatric Oncology and Hematology, Freiburg University Hospital, Freiburg, Germany.
Kordes U; Department of Pediatric Hematology and Oncology, University Medical Center Eppendorf, Hamburg, Germany.
Gruhn B; Department of Pediatrics, Jena University Hospital, Jena, Germany.
Simon T; Department of Pediatric Oncology and Hematology, Cologne University Hospital, Cologne, Germany.
Linderkamp C; Department of Pediatric Oncology and Hematology, Hannover University Hospital, Hanover, Germany.
Sahm F; Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ) and German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany.; Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Taylor L; Pharmacy Department, Heidelberg University Hospital, Heidelberg, Germany.
Freitag A; NCT Trial Center, National Center for Tumor Diseases, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Burhenne J; Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany.
Foerster KI; Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany.
Meid AD; Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany.
Pfister SM; KiTZ Clinical Trial Unit, Hopp Children's Cancer Center Heidelberg (KiTZ), German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany.; Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital, Heidelberg, Germany.; Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.
Karapanagiotou-Schenkel I; NCT Trial Center, National Center for Tumor Diseases, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Witt O; KiTZ Clinical Trial Unit, Hopp Children's Cancer Center Heidelberg (KiTZ), German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany. .; Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital, Heidelberg, Germany. .; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany. .
Pokaż więcej
Źródło :
Clinical epigenetics [Clin Epigenetics] 2019 Dec 10; Vol. 11 (1), pp. 188. Date of Electronic Publication: 2019 Dec 10.
Typ publikacji :
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Histone Deacetylase Inhibitors/*administration & dosage
Neoplasm Recurrence, Local/*drug therapy
Neoplasms/*drug therapy
Vorinostat/*administration & dosage
Adolescent ; Child ; Child, Preschool ; Drug Administration Schedule ; Female ; Histone Deacetylase Inhibitors/adverse effects ; Histone Deacetylase Inhibitors/pharmacokinetics ; Humans ; Leukemia/drug therapy ; Lymphoma/drug therapy ; Male ; Maximum Tolerated Dose ; Survival Analysis ; Treatment Outcome ; Vorinostat/adverse effects ; Vorinostat/pharmacokinetics
Czasopismo naukowe
Tytuł :
Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier.
Autorzy :
Ma W; Center for Pharmacogenetics.; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, 15261, USA.; Current address: School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, P.R. China.
Sun J; Center for Pharmacogenetics.; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, 15261, USA.
Xu J; Center for Pharmacogenetics.; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, 15261, USA.
Luo Z; Center for Pharmacogenetics.; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, 15261, USA.
Diao D; Center for Pharmacogenetics.; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, 15261, USA.
Zhang Z; Center for Pharmacogenetics.; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, 15261, USA.
Oberly PJ; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, 15261, USA.
Minnigh MB; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, 15261, USA.
Xie W; Center for Pharmacogenetics.; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, 15261, USA.
Poloyac SM; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, 15261, USA.
Huang Y; Department of Pharmacology and Chemical Biology.; UPMC Hillman Cancer Center, School of Medicine, University of Pittsburgh, Pittsburgh, PA, 15213, USA.
Li S; Center for Pharmacogenetics.; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, 15261, USA.
Pokaż więcej
Źródło :
Theranostics [Theranostics] 2020 Jan 20; Vol. 10 (6), pp. 2463-2478. Date of Electronic Publication: 2020 Jan 20 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Drug Carriers/*administration & dosage
Prodrugs/*administration & dosage
Tamoxifen/*administration & dosage
Triple Negative Breast Neoplasms/*drug therapy
Vorinostat/*administration & dosage
Animals ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Cell Line, Tumor ; Drug Carriers/pharmacology ; Drug Combinations ; Drug Synergism ; Estrogen Receptor alpha/metabolism ; Female ; Glutathione/metabolism ; Histone Deacetylase Inhibitors/administration & dosage ; Histone Deacetylase Inhibitors/pharmacology ; Humans ; Mice ; Mice, Inbred BALB C ; Micelles ; Nanoparticles/administration & dosage ; Oxidation-Reduction/drug effects ; Polymers/chemistry ; Polymers/pharmacology ; Prodrugs/pharmacology ; Tamoxifen/pharmacology ; Triple Negative Breast Neoplasms/pathology ; Vorinostat/pharmacology
Czasopismo naukowe
Tytuł :
Bortezomib and Vorinostat Therapy as Maintenance Therapy after Autologous Transplant for Multiple Myeloma.
Autorzy :
Holmberg LA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA, .; Department of Medicine, University of Washington, Seattle, Washington, USA, .
Green D; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.; Department of Medicine, University of Washington, Seattle, Washington, USA.
Libby E; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.; Department of Medicine, University of Washington, Seattle, Washington, USA.
Becker PS; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.; Department of Medicine, University of Washington, Seattle, Washington, USA.
Pokaż więcej
Źródło :
Acta haematologica [Acta Haematol] 2020; Vol. 143 (2), pp. 146-154. Date of Electronic Publication: 2019 Aug 21.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Bortezomib/*therapeutic use
Multiple Myeloma/*drug therapy
Vorinostat/*therapeutic use
Bortezomib/adverse effects ; Disease-Free Survival ; Drug Administration Schedule ; Female ; Gastrointestinal Diseases/etiology ; Hematopoietic Stem Cell Transplantation ; Humans ; Male ; Multiple Myeloma/mortality ; Multiple Myeloma/therapy ; Survival Rate ; Transplantation, Autologous ; Treatment Outcome ; Vorinostat/adverse effects
Czasopismo naukowe
Tytuł :
Novel amidase catalysed process for the synthesis of vorinostat drug.
Autorzy :
Singh RV; Fermentation Technology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
Sharma H; Fermentation Technology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
Ganjoo A; Fermentation Technology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.
Kumar A; Instrumentation Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.
Babu V; Fermentation Technology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
Pokaż więcej
Źródło :
Journal of applied microbiology [J Appl Microbiol] 2020 Dec; Vol. 129 (6), pp. 1589-1597. Date of Electronic Publication: 2020 Jul 13.
Typ publikacji :
Journal Article
MeSH Terms :
Amidohydrolases/*metabolism
Histone Deacetylase Inhibitors/*chemical synthesis
Vorinostat/*chemical synthesis
Bacillus/enzymology ; Biotransformation ; Green Chemistry Technology ; Hydroxamic Acids/chemical synthesis ; Temperature
SCR Organism :
Bacillus smithii
Czasopismo naukowe
Tytuł :
Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis.
Autorzy :
Laengle J; Division of General Surgery, Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria.; Ludwig Boltzmann Institute Applied Diagnostics, Medical University of Vienna, Vienna, Austria.
Kabiljo J; Division of General Surgery, Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria.
Hunter L; Division of General Surgery, Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria.
Homola J; Division of General Surgery, Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria.
Prodinger S; Division of General Surgery, Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria.
Egger G; Ludwig Boltzmann Institute Applied Diagnostics, Medical University of Vienna, Vienna, Austria.; Department of Pathology, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria.
Bergmann M; Division of General Surgery, Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria .; Ludwig Boltzmann Institute Applied Diagnostics, Medical University of Vienna, Vienna, Austria.
Pokaż więcej
Źródło :
Journal for immunotherapy of cancer [J Immunother Cancer] 2020 Jan; Vol. 8 (1). Date of Electronic Publication: 2020 Jan 02.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*pharmacology
Breast Neoplasms/*drug therapy
Trastuzumab/*pharmacology
Valproic Acid/*pharmacology
Vorinostat/*pharmacology
Antibody-Dependent Cell Cytotoxicity/drug effects ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/pharmacology ; Breast Neoplasms/immunology ; Breast Neoplasms/pathology ; Case-Control Studies ; Cell Line, Tumor ; Drug Synergism ; Female ; Histone Deacetylase Inhibitors/administration & dosage ; Histone Deacetylase Inhibitors/pharmacology ; Humans ; Phagocytosis/drug effects ; Prognosis ; Receptor, ErbB-2/antagonists & inhibitors ; Receptor, ErbB-2/immunology ; Receptors, IgG/metabolism ; Trastuzumab/administration & dosage ; Valproic Acid/administration & dosage ; Vorinostat/administration & dosage
Czasopismo naukowe
Tytuł :
Hybrid mesoporous nanorods with deeply grooved lateral faces toward cytosolic drug delivery.
Autorzy :
Sun K; Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, No. 174 Shazheng Road, Chongqing 400044, China. .
Ding T; Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, No. 174 Shazheng Road, Chongqing 400044, China. .
Xing Y; Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, No. 174 Shazheng Road, Chongqing 400044, China. .
Mo D; Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, No. 174 Shazheng Road, Chongqing 400044, China. .
Zhang J; Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, No. 174 Shazheng Road, Chongqing 400044, China. .
Rosenholm JM; Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, Tykistökatu 6A, Turku 20520, Finland. .
Pokaż więcej
Źródło :
Biomaterials science [Biomater Sci] 2019 Dec 01; Vol. 7 (12), pp. 5301-5311. Date of Electronic Publication: 2019 Oct 16.
Typ publikacji :
Journal Article
MeSH Terms :
Cytosol/*chemistry
Doxorubicin/*pharmacology
Vorinostat/*pharmacology
Cell Proliferation/drug effects ; Cell Survival/drug effects ; Drug Delivery Systems/methods ; Humans ; Indoles/chemistry ; MCF-7 Cells ; Nanotubes ; Polyethyleneimine/chemistry ; Polymers/chemistry ; Porosity ; Vorinostat/chemistry
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies